Price Watch
NHS Saving £300M by Instructing Providers to Not Prescribe Branded Drugs Including Humira
NHS Has Cut Its Drug Spend by 29%
Payment as a Result Represents How Italy Will Pay for Pricey CAR-T Drug
The Cost of Kymriah Will Be About €300,000 Higher Than Was Reported in July
Elite Indian Research Centers Pursue Strategies to Repurpose Drugs for Cheap & Effective Treatments
Potentially cut treatment costs 85%
U.S. Payer in Minnesota (BCBS) Transcends Existing Paradigm and Offers Free Insulin to Members
Blue Cross and Blue Shield of Minnesota (Blue Cross) will charge $0 co-pay for insulin marking the largest consumer relief for diabetic coverage available through Minnesota health insurance marketplace MNsure. TrialSite News has covered in PriceWatch claims that...
State of California vs. Sutter Health: A Ruthless Monopolist or Visionary-Integrated Health System Simply Executing on Acceptable Models?
The State of California joined a major class action lawsuit against Northern California’s largest health system (Sutter) for illegally using its market dominance to restrict choice and ultimately overcharge for services and is headed for a jury trial. Our PriceWatch...
Clinical Trials and Research News Weekly Roundup for August 3rd 2019
Expensive Cancer Drugs From Gilead and Novartis Losing Patients to Experimental Treatments
Large numbers of U.S. lymphoma patients are opting into experimental treatments in clinical trials versus expensive cell therapies sold by Gilead and Novartis, new data reveals, explaining why sales of the two products haven’t met rosy expectations. Reuters recently...
$3+ Billion Revenue TRUVADA and the Interesting Patent Question Few Knew About
The price of drugs becomes more contentious as some classes of drugs increase in price far faster than prevailing incomes. This overall trend appears to intensify with specialized new therapy classes, such as gene therapy where Novartis recently announced a $2 million...
ICER Analysis Points out Novartis Mayzent Too High
ICER found that tiprotimod (Mayzent) reduced the risk of multiple sclerosis progression as well as decreased inflammatory disease activities however it’s analysis reveals the drug is priced too high for the market. The Institute for Clinical and Economic Review...
FDA Approves Pfizer’s Biosimilar, Zirabev, to Roche’s Avastin
The FDA has approved bevacizumab-bvxr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin, Genentech/Roche), for the treatment of five types of cancer. These cancers include metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic...
